Latest Clinical Outcomes News

LTR Pharma’s intranasal spray OROFLOW® has secured ethics approval for a clinical study targeting oesophageal motility disorders, marking its first foray beyond erectile dysfunction. The study, led by Dr Peter Wu, aims to validate a non-invasive alternative for swallowing difficulties in a market projected to reach US$8.1 billion by 2034.

Cynata Therapeutics (ASX: CYP) has had its trading suspension lifted immediately following the publication of results from its Phase 3 Osteoarthritis and Phase 2 Graft versus Host Disease clinical trials.

Neurizon Therapeutics has secured a critical five-year supply agreement with Elanco Animal Health for GMP-grade monepantel, underpinning the commercialisation readiness of its lead ALS drug candidate NUZ-001.

Paradigm Biopharmaceuticals has completed enrolment ahead of schedule in its pivotal Phase 3 trial for Zilosul®, enrolling 538 patients with knee osteoarthritis and maintaining its timeline for interim and final results.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

IMEXHS Limited exceeded FY25 revenue and EBITDA guidance, driven by strategic contract wins and AI-powered workflow automation. The company projects stronger software growth and sustained profitability in FY26.

Invion Limited has partnered with South Korea's SANGMYUNG Innovation to explore its Photosoft™ photodynamic therapy for wet age-related macular degeneration, addressing a large unmet medical need in ophthalmology.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

Amplia Therapeutics and ANZGOG have initiated a clinical trial to test narmafotinib combined with chemotherapy in ovarian cancer patients unresponsive to platinum-based treatment, aiming to improve surgical outcomes and explore biomarker insights.

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.